Stonegate Updates Coverage on Burcon Nutrascience Corporation (TSX: BU) FY26 Q3
Burcon’s Galesburg production facility represents a pivotal transition from development-stage operations to commercial scale, with 3Q26 revenue of $739,000 reflecting approximately 107% quarter-overquarter growth driven by protein sales and production activity at the site. Notably, the Company entered CY2025 without a production facility and exited the year meeting its revenue target, underscoring the speed of […]
Stonegate Capital Partners Updates Coverage on Nu Skin Enterprises Inc. (NYSE: NUS) 2025 Q4
NUS reported revenue, adj NI, and adj EPS of $370.3M, $14.5M, and $0.29, respectively. This compares to our estimates of $380.2M, $15.1M, and $0.30, respectively. These results were at the low end of revenue guidance and the high end of EPS guidance. Rhyz delivered $48.52M of revenue, including $42.45M from Manufacturing and $6.07M from Rhyz […]
TUNG: Stonegate Updates Coverage on American Tungsten Corp. 3Q25
In July 2025, the Company closed an upsized C$7.0M private placement (14.0M shares issued), strengthening the balance sheet for accelerated field execution. In a subsequent investor update, management highlighted that the upcoming restriction expiry on the July placement shares represents a mechanical unlock rather than incremental dilution. The Company has disclosed a Letter of Interest from the Export-Import Bank of […]
Stonegate’s Impressions from DealFlow 2026
We attended the 2026 DealFlow conference and met with a group of emerging technology and critical materials companies. While business models varied across presenters, a consistent theme was that innovation lives in microcap companies, but forward-looking technology deployment is increasingly constrained by the materials, processing capacity, and regulatory pathways required to build it.